Jasper Therapeutics Stock Investor Sentiment

JSPR Stock  USD 22.81  0.43  1.85%   
Slightly above 69% of Jasper Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Jasper Therapeutics suggests that many traders are alarmed. Jasper Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Jasper Therapeutics. Many technical investors use Jasper Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

Jasper Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Jasper Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at news.google.com         
Insider Trading
Google News at Macroaxis
over three months ago at globenewswire.com         
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
Macroaxis News: globenewswire.com
over three months ago at news.google.com         
Jasper Therapeutics, Inc. Given Average Rating of Buy by Analysts - Defense World
Google News at Macroaxis
over three months ago at globenewswire.com         
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
Macroaxis News: globenewswire.com
over three months ago at investing.com         
Jasper Therapeutics COO sells 21.7k in company stock
Investing News at Macroaxis
over three months ago at investing.com         
Jasper Therapeutics Announces Executive Changes and Stockholder Approvals
Investing News at Macroaxis
over three months ago at investing.com         
Acquisition by Mahal Jeetinder Singh of 900 shares of Jasper Therapeutics at 7.1 subject to Rule 16b...
Investing News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Martell Ron of 10000 shares of Jasper Therapeutics at 23.95 subject to Rule 16b-3
Macroaxis News
over three months ago at finance.yahoo.com         
Heres Why Were Not Too Worried About Jasper Therapeutics Cash Burn Situation
Yahoo News
over three months ago at www.macroaxis.com         
Acquisition by Tucker Edwin Jonathan of 400 shares of Jasper Therapeutics at 4.1735 subject to Rule ...
Macroaxis News
over three months ago at investorplace.com         
Acquisition by Emster Kurt Von of 7500 shares of Jasper Therapeutics at 25.41 subject to Rule 16b-3
sbwire news
over six months ago at benzinga.com         
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congres...
benzinga news
over six months ago at benzinga.com         
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference
benzinga news
over six months ago at news.google.com         
Trading Advice - Stock Traders Daily
Google News at Macroaxis
over six months ago at news.google.com         
Ieq Capital LLC Makes New Investment in Jasper Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Jasper Therapeutics that are available to investors today. That information is available publicly through Jasper media outlets and privately through word of mouth or via Jasper internal channels. However, regardless of the origin, that massive amount of Jasper data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Jasper Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Jasper Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Jasper Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Jasper Therapeutics alpha.

Jasper Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b2a Study of Briquilimab in Asthma
09/10/2024
2
Acquisition by Mahal Jeetinder Singh of 900 shares of Jasper Therapeutics at 7.1 subject to Rule 16b-3
09/12/2024
3
Jasper Therapeutics, Inc. Given Average Recommendation of Buy by Brokerages - MarketBeat
09/23/2024
4
Jasper gains 11 percent on data for briquilimab in urticaria
10/14/2024
5
Jasper Therapeutics Market Outperform Rating Reiterated at JMP Securities
10/15/2024
6
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma Immunology Annual Scientific Meeting
10/24/2024
7
Velan Capital Investment Management LP Increases Stake in Outlook Therapeutics Inc
11/08/2024
8
Jasper Therapeutics to Participate at Upcoming Investor Conferences
11/13/2024
9
Braidwell LP Takes 9.09 Million Position in Jasper Therapeutics, Inc.
11/29/2024

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.